Definition, epidemiology, and prognosis

  • Anthony A Bavry
  • Deepak L Bhatt


Cardiovascular disease is an all-encompassing term that includes diseases of the heart and coronary arteries, as well as diseases in other vascular beds. It is a major cause of death and disability in the United States, Europe, and worldwide (see Figure 1.1) [1]. Cardiovascular disease that is present in vascular beds outside of the coronary arteries is broadly termed peripheral arterial disease, and patients frequently have disease in such overlapping locations (see Figure 1.2) [2]. Examples include carotid and cerebrovascular disease, which are responsible for stroke and transient ischemic attack. Aortoiliac and femoral artery disease are responsible for limb ischemia and claudication. Cardiovascular disease can also manifest itself in stable or unstable forms. Stable coronary artery disease is characterized by stable angina or silent ischemia detected by stress testing, while unstable coronary artery disease (categorized, more generally, as coronary heart disease) includes myocardial infarction and unstable angina. An increasingly used and preferred term for an unstable event is acute coronary syndrome (ACS). ACS encompasses the spectrum from unstable angina to non-ST-elevation myocardial infarction and, finally, ST-elevation myocardial infarction. This chapter will review the epidemiology and prognosis of cardiovascular disease in general, with a special focus on ACS.


Percutaneous Coronary Intervention Acute Coronary Syndrome Unstable Angina Peripheral Arterial Disease Unfractionated Heparin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    American Heart Association. Heart disease and stroke statistics — 2008 update at-a-glance. Available at: Last accessed January 2008.Google Scholar
  2. 2.
    Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295:180–189.CrossRefGoogle Scholar
  3. 3.
    American Heart Association. International cardiovascular disease statistics: statistical fact sheet — populations. 2007 update. Available at: Last accessed December 2007.Google Scholar
  4. 4.
    Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349:1269–1276.CrossRefGoogle Scholar
  5. 5.
    Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3:e442.CrossRefGoogle Scholar
  6. 6.
    The SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy. Primary results of the SYNERGY randomized trial. JAMA 2004; 292:45–54.CrossRefGoogle Scholar
  7. 7.
    Savonitto S, Ardissino D, Granger CB, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA 1999; 281:707–713.CrossRefGoogle Scholar
  8. 8.
    White HD. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomized trial. Lancet 2001; 358:1855–1863.CrossRefGoogle Scholar
  9. 9.
    Fuster V. Epidemic of cardiovascular disease and stroke: the three main challenges. Presented at the 71st Scientific Sessions of the American Heart Association. Circulation 1999; 99:1132–1137.CrossRefGoogle Scholar
  10. 10.
    Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-200. N Engl J Med 2007; 356:2388–2398.CrossRefGoogle Scholar
  11. 11.
    Bhatt DL, Roe MT, Peterson ED, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes. Results from the CRUSADE quality improvement initiative. JAMA 2004; 292:2096–2104.CrossRefGoogle Scholar
  12. 12.
    Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the U.S. from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol 2000; 36:2056–2063.CrossRefGoogle Scholar
  13. 13.
    Unal B, Critchley A, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation 2004; 109:1101–1107.CrossRefGoogle Scholar
  14. 14.
    Laatikainen T, Critchley J, Vartiainen E, et al. Explaining the decline in coronary heart disease mortality in Finland between 1982 and 1997. Am J Epidemiol 2005; 162:764–773.CrossRefGoogle Scholar
  15. 15.
    Bots ML, Grobbee DE. Decline of coronary heart disease mortality in the Netherlands from 1978 to 1985: contribution of medical care and changes over time in presence of major cardiovascular risk factors. J Cardiovasc Risk 1996; 3:271–276.CrossRefGoogle Scholar
  16. 16.
    Lenfant C. Heart research: celebration and renewal. Circulation 1997; 96:3822–3823.Google Scholar
  17. 17.
    Fox KAA, Steg PG, Eagle KA, et al.; for the GRACE Investigators. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 2007; 297:1892–1900.CrossRefGoogle Scholar

Copyright information

© Current Medicine Group, a part of Springer Science+Business Media 2008

Authors and Affiliations

  • Anthony A Bavry
    • 1
  • Deepak L Bhatt
    • 1
  1. 1.Department of Cardiovascular MedicineCleveland ClinicUSA

Personalised recommendations